Upstream Bio: Buy the Reset — Verekitug Momentum Meets a Cheapish Clinical Valuation
Upstream Bio (UPB) is a clinical-stage biotech developing verekitug, a first-in-class TSLP receptor antagonist targeting severe respiratory inflammatory diseases. Recent Phase 2 data in CRSwNP and near-term regulatory interactions for Phase 3 in asthma and CRSwNP create concrete catalysts. The stock has reset from its $33.68 52-week high to about $…